Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Pertuzumab

Review the clinical trials studying pertuzumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-18 of 18

ShortStop-HER2: 12 months vs. 6 months of HER2-targeted Medications for People with HER2+ Breast Cancer who Had a Pathologic Complete Response after Chemotherapy Plus Trastuzumab
Status: Active
Location: 217 locations
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Status: Active
Location: 41 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 33 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery
Status: Active
Location: 15 locations
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 9 locations
A Study of Surgery and Radiotherapy in People with Oligometastatic HER2 Positive Breast Cancer, ARCHER Trial
Status: Active
Location: 7 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 4 locations
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Status: Active
Location: 3 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
Early Clinical Response Correlation to Pathologic Outcome for Treatment in Patients with Invasive Breast Cancer Undergoing Chemotherapy Before Surgery
Status: Active
Location: 2 locations
Radiation Therapy Followed by Trastuzumab and Pertuzumab for the Treatment of HER2 Positive Breast Cancer that has Spread to the Leptomeninges
Status: Active
Location: 2 locations
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Status: Temporarily Closed to Accrual
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California